Linked Life Data

2657302

Source:http://linkedlifedata.com/resource/pubmed/id/2657302

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2657302rdf:typepubmed:Citationlld:pubmed
pubmed-article:2657302lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:2657302lifeskim:mentionsumls-concept:C0150369lld:lifeskim
pubmed-article:2657302lifeskim:mentionsumls-concept:C0026922lld:lifeskim
pubmed-article:2657302lifeskim:mentionsumls-concept:C0003320lld:lifeskim
pubmed-article:2657302lifeskim:mentionsumls-concept:C0010980lld:lifeskim
pubmed-article:2657302lifeskim:mentionsumls-concept:C0023348lld:lifeskim
pubmed-article:2657302lifeskim:mentionsumls-concept:C0220825lld:lifeskim
pubmed-article:2657302lifeskim:mentionsumls-concept:C0332325lld:lifeskim
pubmed-article:2657302lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:2657302lifeskim:mentionsumls-concept:C0031529lld:lifeskim
pubmed-article:2657302lifeskim:mentionsumls-concept:C0205473lld:lifeskim
pubmed-article:2657302lifeskim:mentionsumls-concept:C0349395lld:lifeskim
pubmed-article:2657302pubmed:issue1lld:pubmed
pubmed-article:2657302pubmed:dateCreated1989-6-29lld:pubmed
pubmed-article:2657302pubmed:abstractTextThirty-one dapsone resistant lepromatous leprosy patients receiving clofazimine based therapy were serologically monitored throughout their 5-year period of treatment. Sequentially collected sera were used to examine 4 Mycobacterium leprae antigens to evaluate their usefulness in ELISA's for monitoring the progress of their therapy. The ELISA results were compared with decline in bacterial load over the treatment period and with duration of treatment. In addition the ELISA's were compared with each other. The ELISA's based on the measurement of IgM antibodies to the two neoglycoproteins (NDO and NTO) representing the phenolic glycolipid antigen of M. leprae were found to be the most effective with regard to monitoring treatment. A whole M. leprae based ELISA was less efficient in monitoring treatment because it failed to measure antibodies in 5 out of 31 patients. The ELISA-inhibition test based on the detection of antibodies to a species-specific epitope on the 36 K antigen of M. leprae was less suitable because of persistent reactivity during therapy.lld:pubmed
pubmed-article:2657302pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2657302pubmed:languageenglld:pubmed
pubmed-article:2657302pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2657302pubmed:citationSubsetIMlld:pubmed
pubmed-article:2657302pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2657302pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2657302pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2657302pubmed:statusMEDLINElld:pubmed
pubmed-article:2657302pubmed:monthMarlld:pubmed
pubmed-article:2657302pubmed:issn0305-7518lld:pubmed
pubmed-article:2657302pubmed:authorpubmed-author:HirschD SDSlld:pubmed
pubmed-article:2657302pubmed:authorpubmed-author:DouglasJ TJTlld:pubmed
pubmed-article:2657302pubmed:authorpubmed-author:CellonaR VRVlld:pubmed
pubmed-article:2657302pubmed:authorpubmed-author:MadarangM GMGlld:pubmed
pubmed-article:2657302pubmed:authorpubmed-author:FajardoT TTTlld:pubmed
pubmed-article:2657302pubmed:authorpubmed-author:KlatserP RPRlld:pubmed
pubmed-article:2657302pubmed:authorpubmed-author:AbalosR MRMlld:pubmed
pubmed-article:2657302pubmed:authorpubmed-author:de WitM YMYlld:pubmed
pubmed-article:2657302pubmed:authorpubmed-author:de la CruzE...lld:pubmed
pubmed-article:2657302pubmed:issnTypePrintlld:pubmed
pubmed-article:2657302pubmed:volume60lld:pubmed
pubmed-article:2657302pubmed:ownerNLMlld:pubmed
pubmed-article:2657302pubmed:authorsCompleteYlld:pubmed
pubmed-article:2657302pubmed:pagination8-19lld:pubmed
pubmed-article:2657302pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:2657302pubmed:meshHeadingpubmed-meshheading:2657302-...lld:pubmed
pubmed-article:2657302pubmed:meshHeadingpubmed-meshheading:2657302-...lld:pubmed
pubmed-article:2657302pubmed:meshHeadingpubmed-meshheading:2657302-...lld:pubmed
pubmed-article:2657302pubmed:meshHeadingpubmed-meshheading:2657302-...lld:pubmed
pubmed-article:2657302pubmed:meshHeadingpubmed-meshheading:2657302-...lld:pubmed
pubmed-article:2657302pubmed:meshHeadingpubmed-meshheading:2657302-...lld:pubmed
pubmed-article:2657302pubmed:meshHeadingpubmed-meshheading:2657302-...lld:pubmed
pubmed-article:2657302pubmed:meshHeadingpubmed-meshheading:2657302-...lld:pubmed
pubmed-article:2657302pubmed:meshHeadingpubmed-meshheading:2657302-...lld:pubmed
pubmed-article:2657302pubmed:meshHeadingpubmed-meshheading:2657302-...lld:pubmed
pubmed-article:2657302pubmed:meshHeadingpubmed-meshheading:2657302-...lld:pubmed
pubmed-article:2657302pubmed:meshHeadingpubmed-meshheading:2657302-...lld:pubmed
pubmed-article:2657302pubmed:meshHeadingpubmed-meshheading:2657302-...lld:pubmed
pubmed-article:2657302pubmed:meshHeadingpubmed-meshheading:2657302-...lld:pubmed
pubmed-article:2657302pubmed:meshHeadingpubmed-meshheading:2657302-...lld:pubmed
pubmed-article:2657302pubmed:year1989lld:pubmed
pubmed-article:2657302pubmed:articleTitleEvaluation of Mycobacterium leprae antigens in the serological monitoring of a clofazimine-based chemotherapeutic study of dapsone resistant lepromatous leprosy patients in Cebu, Philippines.lld:pubmed
pubmed-article:2657302pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2657302pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:2657302pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:2657302pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2657302lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2657302lld:pubmed